Beck J C, Mitzner W, Johnson J W, Hutchins G M, Foidart J M, London W T, Palmer A E, Scott R
Pediatr Res. 1981 Mar;15(3):235-40. doi: 10.1203/00006450-198103000-00007.
Pregnant rhesus monkeys (Macaca mulatta) at 67 to 85% of term pregnancy were treated with betamethasone for 3 days and then delivered by cesarean section. These treated fetuses had larger lung volumes (32.6 +/- 1.8 ml/kg of body weight) compared to gestational age-matched controls (22.9 +/- 3.2 ml/kg of body weight; P less than 0.025) but no alterations in surfactant properties as measured by amniotic fluid L/S ratios, alveolar deflation stability, or lung phosphatidylcholine. These findings suggest that betamethasone effects an increase in fetal lung volume by some method other than alteration in alveolar surfactant concentrations. Results also demonstrated an 11% increase in the collagen to elastin concentration in the treated fetuses as compared to the control animals (P less than 0.01), suggesting alterations in lung connective tissue. Morphometric studies done on the air-fixed inflated lung demonstrated a decrease in the number of alveoli per unit volume of lung among the treated animals (0.95 +/- 0.07 x 10(6)) compared to the control animals (1.19 +/- 0.08 x 10(6); P less than 0.025) and a reduction in the mean surface area of the lungs of the treated animals (506 +/- 10 cm2 per cm3) compared to the control animals (561 +/- 9 cm2 per cm3; P less than 0.005). These findings suggest that at least part of the increased maximal lung volumes is related to increased alveolar distensibility. Together, these pressure volume findings, biochemical studies, and morphometric analyses indicate that a major effect of betamethasone on the rhesus fetal lung is to alter lung connective tissue characteristics. Alterations in lung surfactant appear to be of less functional significance in this rhesus fetal model. The disparity between these findings and other animal studies might be due to differences in species, the preparation, or the method of glucocorticoid administration.
对孕期达67%至85%的恒河猴进行为期3天的倍他米松治疗,然后剖宫产分娩。与胎龄匹配的对照组(22.9±3.2毫升/千克体重)相比,这些接受治疗的胎儿肺容积更大(32.6±1.8毫升/千克体重;P<0.025),但通过羊水卵磷脂/鞘磷脂比值、肺泡萎陷稳定性或肺磷脂酰胆碱测定的表面活性物质特性无改变。这些发现表明,倍他米松通过改变肺泡表面活性物质浓度以外的某种方法使胎儿肺容积增加。结果还显示,与对照动物相比,接受治疗的胎儿中胶原蛋白与弹性蛋白浓度增加了11%(P<0.01),提示肺结缔组织发生改变。对空气固定膨胀肺进行的形态计量学研究表明,与对照动物(1.19±0.08×10⁶)相比,接受治疗的动物每单位肺容积中的肺泡数量减少(0.95±0.07×10⁶;P<0.025),且接受治疗的动物肺的平均表面积(每立方厘米506±10平方厘米)低于对照动物(每立方厘米561±9平方厘米;P<0.005)。这些发现表明,至少部分最大肺容积增加与肺泡扩张性增加有关。总之,这些压力-容积研究、生化研究和形态计量分析表明,倍他米松对恒河猴胎儿肺的主要作用是改变肺结缔组织特征。在这个恒河猴胎儿模型中,肺表面活性物质的改变似乎功能意义较小。这些发现与其他动物研究之间的差异可能是由于物种、制备方法或糖皮质激素给药方法的不同。